jRCT2031220162暂停不适用
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-overexpressing gastric/gastroesophageal junction adenocarcinoma (ASPEN-06)
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
- •Adequate Bone Marrow Function.
- •Adequate Renal and Liver Function.
- •Adequate Performance Status.
排除标准
- •Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
- •Prior treatment with any anti-CD47 or anti-SIRP alpha agent.
- •Prior treatment with ramucirumab.
研究者
相似试验
暂停
2 期
A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer (ASPEN-06)gastric/gastroesophageal junction adenocarcinomaJPRN-jRCT2031220162Fanning Philip54
进行中（未招募）
1 期
A Study of ALX148 in Patients with Advanced Gastric CancerEUCTR2021-001008-14-FRALX Oncology Inc.450
进行中（未招募）
1 期
A Study of ALX148 in Patients with Advanced Gastric CancerEUCTR2021-001008-14-CZALX Oncology Inc.450
进行中（未招募）
1 期
A Study of ALX148 in Patients with Advanced Gastric CancerPatients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line).MedDRA version: 20.1Level: LLTClassification code 10017770Term: Gastric carcinomaSystem Organ Class: 100000004864EUCTR2021-001008-14-BEALX Oncology Inc.472
进行中（未招募）
1 期
A Study of ALX148 in Patients with Advanced Gastric CancerEUCTR2021-001008-14-ITALX ONCOLOGY INC450